 |
|
|
| |
Timing of Administration of Anti-PD-1 is Important to Increase HBV-specific Immune Responses in AAV-HBV Mice
|
| |
| |
AASLD 2020 Nov 11-16 virtual
Reported by Jules Levin
Ben De Clerck1, Dorien De Pooter1, Wim Pierson2, Koen Dockx2, Claire Evans3, Helen Horton1,*, Ellen Van Gulck1
1Janssen Infectious Diseases, Janssen Research and Development, a Division of JanssenPharmaceuticaNV,Turnhoutseweg30, 2340 Beerse, Belgium.2Charles River Laboratories, Beerse, Belgium, 3IchorMedical Systems Inc.6310 Nancy Ridge Drive, Suite 107,San Diego, CA 92121, USA.*H Horton was employed by Janssen at the time of the study but is no longer part of the company
References: 1. Babusis D, et al. Mol Pharm 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Agarwal K, et al. J Hepatol 2018;68:672-81; 6. Lampertico P, et al. EASL 2020, abstr 91; 7. Lampertico P, et al. Lancet Gastroenterol Hepatol 2020;5:441-53; 8. Terrault NA, et al. Hepatology 2018;67:1560-99.
|
| |
|
|
|
|
|
